Evidence map›Paper›PMID 42282798›Full record

ArticlebioRxiv : the preprint server for biology2026

Collecting Duct-Targeted Lipid Nanoparticles Deliver

Joshua Giblin, Karla Lambaren, Ronnie LaMastro, Isabella Suzuki, Yi Huang, Rowan Simon, Jose Zarate-Diaz, Ali Osouli, Jessica Pham, Kenneth Hallows and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Joshua GiblinAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.ORCID 0009-0005-0909-6955
Karla LambarenAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Ronnie LaMastroAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Isabella SuzukiAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Yi HuangAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.ORCID 0000-0002-6418-4414
Rowan SimonAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Jose Zarate-DiazAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Ali OsouliAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.
Jessica PhamDepartment of Medicine, Division of Nephrology, University of Vermont Health, Burlington, Vermont, 05405, USA Department of Medicine, Division of Nephrology, University of Vermont Health, Burlington, Vermont, 05405, USA.
Kenneth HallowsDepartment of Medicine, Division of Nephrology, University of Vermont Health, Burlington, Vermont, 05405, USA Department of Medicine, Division of Nephrology, University of Vermont Health, Burlington, Vermont, 05405, USA.ORCID 0000-0002-2964-2440
Eun Ji ChungAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.ORCID 0000-0002-7726-5555

Funding

Resource Development CoreU54DK137516 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Evan Alexander Scott · 2023 to 2026
$4.8M
A Revolutionary Approach for Polycystic Kidney Disease: Oral NanotherapeuticsDP2DK121328 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUNG, EUN JI PAIGE · 2018 to 2018
$2.4M
NIDDK NIH HHS DP2 DK121328NIDDK NIH HHS U54 DK137516
6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), a leading genetic cause of kidney failure, is caused by mutations in the

Indexed as

ADPKDChronic Kidney DiseaseDrug DeliveryGene TherapyLipid NanoparticlesmRNA DeliveryNanomedicine

Identifiers

PMID42282798
PMCPMC13252385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.